Coral Laboratories Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 476417,
    "name": "Coral Labs.",
    "stock_name": "Coral Labs.",
    "full_name": "Coral Laboratories Ltd",
    "name_url": "stocks-analysis/coral-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "433.00",
    "chg": 10.75,
    "chgp": "2.55%",
    "dir": 1,
    "prev_price": "422.25",
    "mcapval": "158.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524506,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE683E01017",
    "curr_date": "Mar 18",
    "curr_time": "",
    "bse_nse_vol": "1.11 k",
    "exc_status": "Active",
    "traded_date": "Mar 18, 2026",
    "traded_date_str": "2026 03 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/coral-labs-476417-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Coral Laboratories Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-laboratories-ltd-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3895898",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CoralLaboratori_mojoScore_3895898.png",
        "date": "2026-03-17 08:24:17",
        "description": "Coral Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 16 March 2026. This revision reflects deteriorating technical indicators, disappointing financial trends, and persistent valuation concerns, signalling heightened caution for investors amid ongoing underperformance relative to the broader market."
      },
      {
        "title": "Coral Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-laboratories-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-financials-3882103",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CoralLaboratori_mojoScore_3882103.png",
        "date": "2026-03-10 08:18:18",
        "description": "Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 9 March 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid persistent operational headwinds and valuation considerations."
      },
      {
        "title": "Coral Laboratories Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-laboratories-ltd-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3857422",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CoralLaboratori_mojoScore_3857422.png",
        "date": "2026-02-26 08:10:38",
        "description": "Coral Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 25 Feb 2026, reflecting deteriorating fundamentals and increasingly negative technical signals. The pharmaceutical company’s financial performance has worsened significantly, with declining sales and profits, while technical indicators have shifted towards bearish trends. This comprehensive downgrade is driven by four key parameters: Quality, Valuation, Financial Trend, and Technicals."
      },
      {
        "title": "Coral Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-laboratories-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-financials-3851069",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CoralLaboratori_mojoScore_3851069.png",
        "date": "2026-02-23 08:09:02",
        "description": "Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Feb 2026, primarily driven by a shift in technical indicators despite ongoing financial challenges. The pharmaceutical company’s Mojo Score now stands at 31.0, reflecting a cautious but slightly improved outlook amid persistent operational headwinds and valuation considerations."
      },
      {
        "title": "Coral Laboratories Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-laboratories-ltd-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3843759",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CoralLaboratori_mojoScore_3843759.png",
        "date": "2026-02-17 08:31:11",
        "description": "Coral Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Feb 2026, reflecting deteriorating fundamentals and increasingly bearish technical indicators. The pharmaceutical company’s financial performance has worsened significantly, with declining sales and profits, while technical analysis signals a negative trend. This comprehensive review examines the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that triggered the rating change."
      },
      {
        "title": "Are Coral Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-coral-laboratories-ltd-latest-results-good-or-bad-3840422",
        "imagepath": "",
        "date": "2026-02-14 19:47:04",
        "description": "Coral Laboratories Ltd's latest financial results for Q3 FY26 indicate significant operational challenges. The company reported net sales of ₹21.56 crores, reflecting a year-on-year decline of 6.22%. This continues a troubling trend, as the company has experienced declining revenues throughout FY2026, with previous quarters showing even steeper declines. The net profit for the quarter stood at ₹2.78 crores, which represents a substantial year-on-year decrease of 54.70%. \n\nThe operating profit, excluding other income, fell sharply to ₹1.89 crores, marking a dramatic decline of 70.05% compared to the same quarter last year. This resulted in an operating margin of 8.77%, the lowest in seven quarters, down from 27.45% a year earlier. The profit after tax (PAT) margin also contracted significantly to 12.89%, down from 26.71% in Q3 FY25.\n\nA critical concern highlighted in the results is the company's increasing r..."
      },
      {
        "title": "Coral Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/coral-laboratories-ltd-is-rated-sell-3838983",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CoralLaboratori_mojoScore_3838983.png",
        "date": "2026-02-14 10:10:44",
        "description": "Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Coral Laboratories Q3 FY26: Profit Plunges 55% as Operational Challenges Mount",
        "link": "https://www.marketsmojo.com/news/result-analysis/coral-laboratories-q3-fy26-profit-plunges-55-as-operational-challenges-mount-3839449",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CoralLaboratori_quaterlyResult_3839449.png",
        "date": "2026-02-14 08:47:28",
        "description": "Coral Laboratories Limited, a Vadodara-based pharmaceutical formulations manufacturer, reported deeply disappointing third-quarter results for FY2026, with net profit collapsing 54.70% year-on-year to ₹2.78 crores from ₹6.14 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹173.00 crores, saw its stock trading at ₹479.90 on February 13, down 1.41% on the day and languishing 43.60% below its 52-week high of ₹850.90."
      },
      {
        "title": "Are Coral Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-coral-laboratories-ltd-latest-results-good-or-bad-3838226",
        "imagepath": "",
        "date": "2026-02-13 19:59:14",
        "description": "Coral Laboratories Ltd's latest financial results for Q2 FY26 present a complex picture. The company reported a net profit of ₹5.82 crores, which reflects a significant sequential recovery of 127.34% from the previous quarter. However, this figure represents an 8.78% decline compared to the same quarter last year. Revenue for the quarter was ₹19.03 crores, showing a slight sequential increase of 1.12% but a substantial year-on-year decrease of 40.96% from ₹32.23 crores in Q2 FY25. \n\nThe operating margin improved markedly to 25.91%, up 1433 basis points from the previous quarter and 571 basis points year-on-year, indicating effective cost management despite the revenue challenges. Similarly, the profit after tax (PAT) margin reached 30.58%, reflecting a strong sequential gain but a decline from the previous year.\n\nDespite these positive margin developments, the significant year-on-year revenue decline raises..."
      }
    ],
    "total": 155,
    "sid": "476417",
    "stock_news_url": "https://www.marketsmojo.com/news/coral-laboratories-476417"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On February 13 2026",
      "datetime": "13-Feb-2026",
      "details": "Outcome of board meeting held on Friday 13 2026",
      "source": "BSE"
    },
    {
      "caption": "Financial Result For The Quarter Ended December 31 2026",
      "datetime": "13-Feb-2026",
      "details": "Submission of financial result for the quarter ended December 31 2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Intimation Of Board Meeting To Consider Financial Result For The Quarter And Nine Months Ended On December 31 2025",
      "datetime": "05-Feb-2026",
      "details": "Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve Intimation of Board meeting to consider financial result for the quarter and nine months ended on December 31 2025 and other general business matter.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Coral Laboratories Ltd has declared <strong>15%</strong> dividend, ex-date: 19 Sep 25",
          "dt": "2025-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Coral Laboratories Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-03-17 08:24:17

Coral Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 16 March 2026. This revision reflects deteriorating technical indicators, disappointing financial trends, and persistent valuation concerns, signalling heightened caution for investors amid ongoing underperformance relative to the broader market.

Read full news article

Coral Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Financials

2026-03-10 08:18:18

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 9 March 2026, driven primarily by a shift in technical indicators despite ongoing financial challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid persistent operational headwinds and valuation considerations.

Read full news article

Coral Laboratories Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-02-26 08:10:38

Coral Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 25 Feb 2026, reflecting deteriorating fundamentals and increasingly negative technical signals. The pharmaceutical company’s financial performance has worsened significantly, with declining sales and profits, while technical indicators have shifted towards bearish trends. This comprehensive downgrade is driven by four key parameters: Quality, Valuation, Financial Trend, and Technicals.

Read full news article

Coral Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Financials

2026-02-23 08:09:02

Coral Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 20 Feb 2026, primarily driven by a shift in technical indicators despite ongoing financial challenges. The pharmaceutical company’s Mojo Score now stands at 31.0, reflecting a cautious but slightly improved outlook amid persistent operational headwinds and valuation considerations.

Read full news article

Coral Laboratories Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-02-17 08:31:11

Coral Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Feb 2026, reflecting deteriorating fundamentals and increasingly bearish technical indicators. The pharmaceutical company’s financial performance has worsened significantly, with declining sales and profits, while technical analysis signals a negative trend. This comprehensive review examines the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that triggered the rating change.

Read full news article

Are Coral Laboratories Ltd latest results good or bad?

2026-02-14 19:47:04

Coral Laboratories Ltd's latest financial results for Q3 FY26 indicate significant operational challenges. The company reported net sales of ₹21.56 crores, reflecting a year-on-year decline of 6.22%. This continues a troubling trend, as the company has experienced declining revenues throughout FY2026, with previous quarters showing even steeper declines. The net profit for the quarter stood at ₹2.78 crores, which represents a substantial year-on-year decrease of 54.70%. The operating profit, excluding other income, fell sharply to ₹1.89 crores, marking a dramatic decline of 70.05% compared to the same quarter last year. This resulted in an operating margin of 8.77%, the lowest in seven quarters, down from 27.45% a year earlier. The profit after tax (PAT) margin also contracted significantly to 12.89%, down from 26.71% in Q3 FY25. A critical concern highlighted in the results is the company's increasing r...

Read full news article

Coral Laboratories Ltd is Rated Sell

2026-02-14 10:10:44

Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Coral Laboratories Q3 FY26: Profit Plunges 55% as Operational Challenges Mount

2026-02-14 08:47:28

Coral Laboratories Limited, a Vadodara-based pharmaceutical formulations manufacturer, reported deeply disappointing third-quarter results for FY2026, with net profit collapsing 54.70% year-on-year to ₹2.78 crores from ₹6.14 crores in Q3 FY25. The micro-cap pharmaceutical company, with a market capitalisation of ₹173.00 crores, saw its stock trading at ₹479.90 on February 13, down 1.41% on the day and languishing 43.60% below its 52-week high of ₹850.90.

Read full news article

Are Coral Laboratories Ltd latest results good or bad?

2026-02-13 19:59:14

Coral Laboratories Ltd's latest financial results for Q2 FY26 present a complex picture. The company reported a net profit of ₹5.82 crores, which reflects a significant sequential recovery of 127.34% from the previous quarter. However, this figure represents an 8.78% decline compared to the same quarter last year. Revenue for the quarter was ₹19.03 crores, showing a slight sequential increase of 1.12% but a substantial year-on-year decrease of 40.96% from ₹32.23 crores in Q2 FY25. The operating margin improved markedly to 25.91%, up 1433 basis points from the previous quarter and 571 basis points year-on-year, indicating effective cost management despite the revenue challenges. Similarly, the profit after tax (PAT) margin reached 30.58%, reflecting a strong sequential gain but a decline from the previous year. Despite these positive margin developments, the significant year-on-year revenue decline raises...

Read full news article

View All News